HIMS&HERS is a great company…BUT!

Key points

• Explosive telehealth disruption: The company is successfully modernizing the stagnant healthcare sector with highly personalized solutions, achieving massive revenue growth that exceeded 900% in 2024 and officially turning a net profit.

• Forecaster’s predictive precision: While the Fundamental layer of the Forecaster software highlighted a remarkably resilient business with a high Altman Z-score, the platform’s technical indicators and seasonality models correctly warned of an unfinished downward trend.

• Massive newly created undervaluation: The market recently validated the software’s cautious projections, driving the stock price down sharply from $28 to $15, which shifts the asset into a highly lucrative territory at 50% below its fair value.

Transforming an industry that has remained largely stagnant for two decades requires a unique approach, and telehealth innovators are currently leading a massive paradigm shift. Hims & Hers stands out as a fascinating enterprise that is aggressively redesigning the patient experience. However, rapid expansion alone does not automatically translate into a sound investment. To determine whether it is time to allocate capital or exercise patience, a deep dive into the company’s metrics is required, utilizing the advanced analytical capabilities of the Forecaster software to uncover the true underlying value.

Decoding the business model using the Forecaster software

To truly grasp the mechanics of this operation, it is essential to consult the Fundamental layer of the Forecaster. Utilizing the platform’s artificial intelligence to summarize the business model reveals a straightforward reality: Hims & Hers operates a highly transformative platform in the telehealth sector, seamlessly combining modern technology with personalized healthcare services.

This presents a highly compelling narrative. Even with immense capital flowing through the global healthcare industry, significant modernization has been entirely absent for the past twenty years. Hims & Hers has successfully engineered a completely different customer and user experience compared to traditional healthcare providers. A quick review of their digital storefront highlights specialized solutions for weight loss, sexual health, and hair regrowth. By heavily backing these emerging lifestyle and wellness trends, the company is injecting fresh innovation into a highly promising sector.

Analyzing the financials within the Fundamental layer

Turning to the financial data within the Forecaster, the historical performance shows that the company only achieved profitability recently, officially closing in profit during 2024. Because of this recent shift, traditional formulas for calculating fair value must be temporarily discarded. Instead, the most accurate metric to employ for a newly profitable entity is the Enterprise Value on Sales (EV/Sales) ratio.

Initial analysis within the software indicated an interesting setup: the calculated fair value stood at $32, while the current trading price was hovering at $28. It is worth noting that stock prices were significantly higher when this initial assessment was compiled. This specific data originates from an extract of a free weekly webinar dedicated to uncovering the best trading and investing opportunities for the upcoming week, with access links readily available in the event description.

Diving deeper into the Fundamental layer to assess financial solidity yields a highly reassuring Altman Z-score of 20.42. This exceptionally high score indicates a remarkably low risk of bankruptcy. When examining the value generation area of the software, the data classifies the company as resilient rather than fully robust. The primary reason for this distinction is the corporate strategy of issuing new shares rather than executing stock buybacks.

Despite the lack of buybacks, the top-line growth is undeniably explosive. The five-year growth rate for revenues reached an astonishing 900% in 2024. Furthermore, looking at the Trailing Twelve Months (TTM)—covering the last four available quarters—the revenue growth rate has skyrocketed to more than 1,000%. The net income trajectory is equally positive; not only did 2024 close in profit, but the TTM profit is even higher, showing an accelerating growth rate. Customer acquisition is clearly scaling up rapidly.

A dramatic market update validates the technical projections

While the original evaluation indicated a modest undervaluation, the stock market moves swiftly. This analysis was conducted just a few days ago, and in the intervening time, the market has completely validated the cautious technical outlook. The stock price has experienced a steep decline, dropping sharply from the initial $28 down to $15.

Because of this dramatic price action, Hims & Hers is now sitting at a massive 50% below its fair value. This sudden shift drastically alters the investment landscape, turning what was once a mildly interesting proposition into a deeply discounted opportunity.

Cash flow strength and a strategic focus on rapid growth

Reviewing the cash flow metrics provides further encouragement. The company has maintained a positive cash flow since 2023. While the TTM cash flow is not currently exhibiting aggressive growth, the organization is undeniably well-capitalized and holding strong cash reserves.

Market positioning also plays a crucial role in the stock’s future trajectory. Currently sitting at a market capitalization of roughly $6 billion, Hims & Hers remains a relatively small player compared to the giants of the S&P 500. It is currently nested within the S&P Midcap and the Russell 2000 indices, meaning it is still flying under the radar of massive institutional investors.

By utilizing the Transcription part of the Forecaster and asking the AI to highlight the most crucial earnings data, the overwhelming takeaway is the exceptionally strong revenue growth, which has increased by 49% year-over-year. The corporate strategy here mirrors that of companies like Duolingo: an intense focus on relentless growth over immediate monetization. For long-term shareholders, capturing dominant market share early is often the most rewarding trajectory.

Timing the entry with Forecaster technical indicators

Before the recent price collapse to $15, the Overbought/Oversold page of the Forecaster painted a cautionary picture. Even when prices seemed low at $28, the indicators strongly suggested that the downward trend had not yet concluded. The Market mood meter had consistently failed to enter positive territory, acting as a clear warning sign that the stock had further room to fall.

Historical patterns confirmed this bearish short-term outlook. The Seasonality metrics showed the current price action closely mirroring the behavior seen in 2022. The midterm seasonality models specifically warned of a potential drop of more than 25% in the following month.

Furthermore, checking the Projection tab of the Forecaster offered the final piece of the puzzle. The system provided highly robust and probable feedback—classified as a “strong” signal—forecasting a severe 35% drop. When the stock was at $28, it was technically undervalued by only 12%. As the famous investing philosophy goes, Warren Buffett likely wouldn’t touch a company with such a slim margin of safety. However, the exact drop predicted by the Forecaster materialized perfectly, bringing the asset to the highly lucrative 50% undervaluation mark.

Strategic placement in the Forecaster watch lists

Hims & Hers undoubtedly possesses the fundamental strength and disruptive market presence to become a 10x investment in the future. The healthcare sector is ripe for the exact brand of telehealth innovation they are providing.

Because patience is the ultimate tool in investing, the strategy involved utilizing the watch lists function within the Forecaster. The stock was specifically assigned to the “missed” watch list—a dedicated space for tracking promising companies that were overlooked by mainstream analysts and financial YouTubers for 2026. The overarching game plan was to hold off and wait for a significant market correction before accumulating shares. Now that the anticipated plunge to $15 has successfully occurred, the waiting period might finally be over.